TriangleNCT00511238 · OUTCOME
Duration of Response (A0 Only)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- days
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Response assessments same as described in primary outcome measure
What was measured
Duration of response (DOR) was calculated separately for subjects with clinical benefit response or overall response. DOR is defined as the time from first evidence of PR or better (for overall response) and MR or better (for clinical benefit response) to start of disease progression or death.
Analysis population: Subjects with overall response within the response-evaluable population were included in the analysis of DOR. See analysis population description of response-evaluable population above.
Groups in this outcome
Carfilzomib (A0) for (ORR)
Subjects will receive carfilzomib 20 mg/m2 intravenously on Days 1, 2, 8, 9, 15, and 16 of a 28 day cycle
| Group | Source count |
|---|---|
| Carfilzomib (A0) for (ORR) | 7 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Carfilzomib (A0) for (ORR) | 219 | Not reported | 57 | NA | The upper limit of the 95% confidence interval was not calculable/available (not estimable \[NE\]) because an insufficient number of participants reached the event at the final time point for assessment (3 of 7 responders had an event). |
Complete source fields
- classes
- categories
- measurements
- comment
- The upper limit of the 95% confidence interval was not calculable/available (not estimable \[NE\]) because an insufficient number of participants reached the event at the final time point for assessment (3 of 7 responders had an event).
- group Id
- OG000
- lower Limit
- 57
- upper Limit
- NA
- value
- 219
- denoms
- counts
- group Id
- OG000
- value
- 7
- units
- Participants
- description
- Duration of response (DOR) was calculated separately for subjects with clinical benefit response or overall response. DOR is defined as the time from first evidence of PR or better (for overall response) and MR or better (for clinical benefit response) to start of disease progression or death.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Subjects will receive carfilzomib 20 mg/m2 intravenously on Days 1, 2, 8, 9, 15, and 16 of a 28 day cycle
- id
- OG000
- title
- Carfilzomib (A0) for (ORR)
- param Type
- MEDIAN
- population Description
- Subjects with overall response within the response-evaluable population were included in the analysis of DOR. See analysis population description of response-evaluable population above.
- reporting Status
- POSTED
- time Frame
- Response assessments same as described in primary outcome measure
- title
- Duration of Response (A0 Only)
- type
- SECONDARY
- unit Of Measure
- days
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice